Business
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment
Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment.
About this update from Fifty 1 Labs Inc.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Fifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment\r\n \r\n \r\n\r\n\r\nFifty 1 Labs, Inc. Announces Bold Expansion Plan Powered by Nobel Prize Laureate Management Team, Cutting-Edge AI Healthcare Innovation and $350K Leadership Investment\r\nCompany Targets OTCQB and NASDAQ Uplisting With Breakthroughs in Drug Repurposing, Functional Medicine, and Strategic Acquisitions\r\n\r\n\r\n\r\n\r\n\r\nSEATTLE, July 08, 2025 (GLOBE NEWSWIRE) -- via IBN -- Fifty 1 Labs, Inc. (OTC: FITY), a Nevada-based pioneer in AI-driven drug repurposing and AI-driven functional medicine, today unveiled a transformative Game Plan to achieve a $50 million valuation and lead the $320.6 billion functional medicine market (CAGR 10.9%, Grand View Research). Powered by a dynamic management team, a $350,000 personal investment from its officers and directors, and the innovative AI platform of its wholly owned subsidiary, Fifty1 AI Labs LLC, FITY is set for exponential growth. The Company targets uplisting to the OTCQB Venture Market by Q1 2026, with a longer-term objective of listing on the NASDAQ Capital Market. Leadership has deferred all salaries until the $50 million milestone is met, underscoring their unwavering commitment to shareholders. Game Plan: A Blueprint for Biotech Innovation FITY's Game Plan is a bold roadmap to reshape healthcare through AI-driven drug repurposing and AI-driven functional medicine, targeting high-growth areas like preventative healthcare in the $5.68 trillion biotech market (CAGR 13.8%, Precedence Research). Key initiatives include: \r\n Uplisting to OTCQB and NASDAQ: Secure OTCQB listing by the first quarter of 2026, and NASDAQ Capital Market listing in the next few years, boosting investor visibility and liquidity.\r\n Strategic Acquisitions: Pursue the acquisition of a biotech startup in the $5–10 million range, with additional targeted acquisitions planned to strengthen R&D capabilities and expand market presence.\r\n Digital Engagement: Launch a minimum viable product website by July 24, 2025, and a fully interactive website by July 31, 2025, at www.fifty1AIlabs.com to connect with shareholders and customers.\r\n R&D Leadership: Invest $1,000,000 in Fifty1 AI Labs LLC to ad...